125,694 Shares in Pfizer Inc. $PFE Acquired by Caxton Associates LLP

Key Points

• Caxton Associates LLP has acquired 125,694 shares of Pfizer Inc. valued at approximately $3,185,000 during the first quarter.
• Several institutional investors, including Gould Capital LLC and North Capital Inc., have recently adjusted their stakes in Pfizer, contributing to a total of 68.36% of the stock owned by hedge funds and institutional investors.
• Pfizer recently declared a quarterly dividend of $0.43 per share, yielding 6.9%, with an annual dividend payout ratio of 91.49%.

Caxton Associates LLP bought a new position in shares of Pfizer Inc. (NYSE:PFE - Free Report) during the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor bought 125,694 shares of the biopharmaceutical company's stock, valued at approximately $3,185,000.

Several other large investors have also recently added to or reduced their stakes in PFE. Gould Capital LLC increased its stake in Pfizer by 97.2% during the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock worth $27,000 after buying an additional 493 shares during the period. GKV Capital Management Co. Inc. purchased a new stake in shares of Pfizer in the 1st quarter valued at approximately $27,000. North Capital Inc. purchased a new stake in shares of Pfizer in the 1st quarter valued at approximately $28,000. Bayforest Capital Ltd purchased a new stake in shares of Pfizer in the 1st quarter valued at approximately $28,000. Finally, Bernard Wealth Management Corp. purchased a new stake in shares of Pfizer in the 4th quarter valued at approximately $30,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on PFE shares. Jefferies Financial Group increased their price objective on shares of Pfizer from $32.00 to $33.00 and gave the company a "buy" rating in a research report on Wednesday, May 21st. Bank of America increased their price objective on shares of Pfizer from $27.00 to $28.00 and gave the company a "neutral" rating in a research report on Wednesday, August 6th. HSBC dropped their target price on shares of Pfizer from $27.00 to $26.00 and set a "buy" rating on the stock in a research report on Monday, May 19th. Morgan Stanley increased their target price on shares of Pfizer from $32.00 to $33.00 and gave the company an "equal weight" rating in a research report on Wednesday, August 6th. Finally, Berenberg Bank dropped their price objective on Pfizer from $28.00 to $25.00 and set a "hold" rating on the stock in a report on Thursday, May 29th. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and an average target price of $28.12.

Pfizer Stock Performance

NYSE:PFE opened at $24.86 on Monday. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. The firm has a 50-day moving average price of $24.85 and a two-hundred day moving average price of $24.34. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $30.43. The company has a market capitalization of $141.31 billion, a P/E ratio of 13.22, a price-to-earnings-growth ratio of 0.88 and a beta of 0.55.

Pfizer (NYSE:PFE - Get Free Report) last posted its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The firm had revenue of $14.65 billion during the quarter, compared to the consensus estimate of $13.43 billion. During the same period last year, the firm posted $0.60 EPS. The firm's revenue for the quarter was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th were paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 6.9%. The ex-dividend date of this dividend was Friday, July 25th. Pfizer's dividend payout ratio (DPR) is currently 91.49%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.